Teva Canada, 2020 file: Raysonho / Wikimedia (CC0, cropped)
Teva Pharmaceutical Industries set a target Wednesday of $6 billion to $7 billion in annual innovative-medicines revenue by 2030, using its first R&D Day to outline the next stage of its shift toward higher-value treatments.
The company said its pipeline could support one innovative-medicine launch a year over the next five years. That is a development ambition, not a guarantee: experimental medicines must still complete clinical testing and win regulatory approval.
Teva also outlined a free-cash-flow target above $3.5 billion by 2030 and mid-single-digit growth in total revenue from 2026 through 2030. The announcement was a research-and-development strategy update, not a quarterly earnings release.
The company said its late-stage pipeline has more than $10 billion in combined peak-sales potential. That figure is not risk-adjusted and is subject to regulatory approvals; it should not be read as expected revenue already secured.
Among the research updates, Teva said an anti-IL-15 treatment met its primary endpoint in a Phase 2a study in celiac disease. A Phase 2b study is expected to begin in the second half of 2027. The treatment remains investigational, not approved for patients with celiac disease.
Teva said innovative medicines now account for more than 20% of its revenue and that it has ten innovative pipeline programs. Its longer-term plans pair that business with generics and biosimilars, while funding research, launches and business development.
The 2030 targets depend on clinical results, approvals and commercial execution. They are forward-looking company goals, not assured outcomes.
Company source: Teva’s R&D Day release.
JBizNews Desk | Tel Aviv
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
